CBD Market Report
Project CBD
FEBRUARY 28, 2023
Despite the companies’ submitting the required data demonstrating the “reasonable expectation of safety under the recommended conditions of use,” the FDA rejected the applications, citing the drug preclusion clause. Available at: www.fda.gov/media/131878/download. May not be reprinted without permission from the source. 2021.108680.
Let's personalize your content